Novabay Pharmaceuticals (NBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Sales | 3,999 | 2,265 | 2,133 | 1,807 | 1,888 |
| Cost of Goods | 1,908 | 712 | 614 | 455 | 813 |
| Gross Profit | 2,091 | 1,553 | 1,519 | 1,352 | 1,075 |
| Operating Expenses | 6,193 | 4,554 | 3,992 | 3,327 | 3,646 |
| Operating Income | -3,194 | -2,289 | -1,859 | -1,520 | -1,758 |
| Other Income | 3,036 | 0 | 0 | 2 | 8 |
| Pre-tax Income | -158 | -2,289 | -1,859 | -1,518 | -1,750 |
| Income Tax | N/A | N/A | N/A | N/A | -6 |
| Net Income Continuous | -158 | -2,289 | -1,859 | -1,518 | -1,744 |
| Net Income | $-158 | $-2,289 | $-1,859 | $-1,518 | $-1,744 |
| EPS Basic Total Ops | -24.98 | -61.13 | -48.90 | -48.90 | -24.45 |
| EPS Basic Continuous Ops | -3.19 | -62.30 | -53.40 | -44.42 | -36.58 |
| EPS Diluted Total Ops | -24.98 | -61.13 | -48.90 | -48.90 | -24.45 |
| EPS Diluted Continuous Ops | -3.19 | -62.30 | -53.40 | -44.42 | -36.58 |
| EBITDA(a) | $-3,107 | $-2,277 | $-1,848 | $-1,511 | $-1,747 |